[Prevention of thromboembolism with heparin-DHE--safety and trends].
Perioperative thrombosis prophylaxis with low dose heparin-DHE. Efficiently protects against thromboembolic complications. Side effect such as haemorrhage or vasospasms are rarely seen. The known contraindications of DHE have been respected strictly. The latest development is low molecular heparin which has been tried out and evaluated on the ground of a controlled double blind study of 259 patients undergoing general surgery. The study shows the following advantages: thrombosis prophylaxis by one injection pro die only. This means less work for the staff and lower costs. Further studies on low molecular heparin are necessary.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic; D004087:Dihydroergotamine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011897:Random Allocation; D012306:Risk; D013923:Thromboembolism / Q000517:prevention & control*
D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight; C031388:heparin-dihydergot; D004087:Dihydroergotamine; D006493:Heparin
Thromboembolieprophylaxe mit Heparin-DHE--Gesichertes und Trends.